frameshiftstimul
fss
rna
regulatori
rna
critic
import
viru
life
cycl
posit
novel
target
antihiv
drug
develop
report
synthesi
evalu
triazolecontain
compound
abl
bind
fss
high
affin
select
readili
access
synthet
compound
less
toxic
previous
report
olefin
congen
show
first
time
fsstarget
compound
antivir
activ
replicationcompet
hiv
human
cell
includ
highli
cytopath
multidrugresist
strain
result
support
viabil
fss
rna
therapeut
target
gener
highlight
opportun
synthet
moleculemedi
interfer
protein
recod
wide
rang
organ
rapidli
expand
recognit
rna
high
signific
therapeut
target
addit
import
code
region
mrna
noncod
rna
sequenc
includ
mirna
lncrna
other
structur
regulatori
region
rna
found
within
code
sequenc
demonstr
critic
role
human
health
diseas
recent
work
reveal
util
rnatarget
compound
treatment
splice
diseas
candid
antibiot
via
modul
bacteri
riboswitch
activ
final
rna
potenti
therapeut
signific
also
identifi
pathogen
agent
includ
virus
hiv
sar
htlv
one
rna
sequenc
particularli
attract
model
system
fundament
studi
rnatarget
compound
design
potenti
drug
target
highli
stabl
rna
hairpin
serv
regulatori
element
translat
gag
gagpol
polyprotein
specif
mrna
encod
protein
carri
stop
codon
end
gag
gene
signific
major
case
ribosom
read
end
gag
read
frame
reach
stop
codon
produc
gag
polyprotein
process
yield
structur
protein
howev
approxim
gagpol
mrna
translat
event
interact
ribosom
particular
stemloop
within
gagpol
transcript
frameshift
stimul
stemloop
fss
rna
caus
slip
back
one
nucleotid
upstream
urich
slipperi
sequenc
figur
ribosom
resum
process
slipperi
sequenc
indic
red
frameshiftstimul
stemloop
fss
employ
studi
highlight
yellow
box
translat
new
read
frame
ribosom
frameshift
longer
recogn
gag
stop
codon
instead
continu
process
mrna
fulllength
gagpol
produc
pol
consist
vital
enzym
includ
hiv
proteas
revers
transcriptas
integras
absolut
requir
product
infecti
viron
although
detail
mechan
frameshift
remain
elus
high
conserv
fss
rna
sequenc
isol
combin
experiment
work
demonstr
chang
frameshift
frequenc
function
mutat
rna
suggest
presenc
structur
critic
alter
gag
gagpol
ratio
either
direct
found
substanti
reduc
infect
product
virion
thu
compound
abl
bind
rna
influenc
frameshift
posit
new
class
antihiv
agent
address
gener
problem
identifi
select
binder
biomed
relev
rna
target
develop
discoveri
protocol
base
initi
rapid
identif
hit
molecul
use
resinbound
dynam
combinatori
chemistri
rbdcc
follow
iter
medicin
chemistri
approach
affin
matur
part
process
necessari
convert
disulfid
moieti
use
mutat
group
rbdcc
nonreduc
function
group
suitabl
studi
biolog
context
thu
far
focus
use
olefin
disulfid
isoster
appropri
bioisoster
sinc
geometri
mean
ident
strategi
result
compound
relev
activ
vitro
vivo
includ
compound
target
fss
prior
effort
toward
enhanc
affin
select
fsstarget
compound
via
direct
analog
synthesi
culmin
recent
disclosur
seri
nmethyl
amid
except
high
affin
select
fss
rna
compound
exampl
figur
found
dissoci
constant
k
fss
rna
nm
via
surfac
plasmon
reson
approxim
tighter
bind
compound
also
found
inhibit
hiv
infect
pseudotyp
singlecycl
hiv
assay
also
success
employ
approach
address
sequenc
relev
triplet
repeatmedi
splice
diseas
myoton
dystrophi
type
yield
compound
activ
mous
model
affin
activ
rnabind
compound
synthes
date
incorpor
olefin
bioisoster
encourag
sought
altern
disulfid
replac
would
permit
simpler
readili
scalabl
synthesi
end
substructur
seem
particularli
attract
given
highli
robust
metalcatalyz
huisgen
cycloaddit
condit
develop
synthesi
despit
immens
bodi
literatur
use
triazol
chemistri
includ
peptidomimet
rnabind
compound
rel
exampl
substructur
serv
bioisoster
replac
disulfid
addit
first
report
use
suga
colleagu
success
employ
intramolecular
triazol
format
disulfid
replac
context
bicycl
peptid
rutheniumcatalyz
cycliz
strategi
describ
kolmar
group
synthesi
triazol
analog
cyclic
disulfidecontain
trypsin
inhibitor
latter
case
inhibitori
activ
triazol
peptidomimet
found
similar
parent
disulfid
subtl
differ
nativ
disulfid
isoster
triazol
also
report
neg
effect
biolog
activ
howev
caus
unfold
insulin
glargin
analog
structur
similar
triazol
disubstitut
olefin
disulfid
readili
appar
dft
calcul
figur
howev
differ
also
obviou
calcul
local
minimum
angl
consist
wellestablish
refer
valu
lcystin
disulfid
bond
torsion
landscap
quit
differ
either
olefin
triazol
distanc
flank
alpha
carbon
similar
tran
olefin
vs
disulfid
distanc
slightli
shorter
ci
olefin
longer
triazol
electrostat
potenti
surfac
also
quit
differ
three
substructur
triazol
present
overal
neg
charg
surfac
nonetheless
pendant
function
capabl
posit
similar
orient
thu
anticip
would
suitabl
disulfid
olefin
substitut
fss
bind
compound
peptid
precursor
compound
synthes
solid
phase
use
method
analog
previous
report
result
synthesi
analog
also
provid
us
first
opportun
synthes
test
nonsymmetr
nmethyl
pattern
eg
compound
previou
attempt
accomplish
use
onbead
olefin
crossmetathesi
met
modest
yield
best
cu
catalyz
huisgen
cycloaddit
conduct
resin
use
methodolog
describ
meldal
cowork
case
method
provid
desir
compound
follow
cleavag
resin
concomit
deprotect
singl
major
peak
analyt
hplc
previou
work
monitor
bindingdepend
quench
benzo
g
quinolin
fluoresc
determin
dissoci
constant
unfortun
initi
attempt
measur
affin
triazolecontain
compound
fss
rna
fluoresc
titrat
unsuccess
due
irrevers
photobleach
compound
therefor
measur
bind
constant
surfac
plasmon
reson
spr
tabl
assay
rna
immobil
spr
chip
compound
flow
solut
allow
determin
kinet
rate
constant
bind
well
thermodynam
paramet
comparison
measur
affin
indic
substitut
triazol
olefin
effect
affin
within
error
nmethyl
modest
effect
affin
compound
display
highest
affin
bind
constant
tighter
previous
describ
nmethyl
amid
analog
affin
enhanc
larg
driven
increas
onrat
k
consist
hypothesi
nmethyl
reduc
complex
ground
state
conform
ensembl
favor
conform
conform
abl
bind
rna
known
propens
nmethyl
alter
peptid
conform
order
test
select
spr
measur
made
use
competit
assay
mixtur
compound
plu
excess
yeast
trna
rel
compound
concentr
solut
flow
spr
chip
cours
constitut
even
larger
excess
trna
amount
fss
rna
immobil
sensor
chip
repres
stringent
assay
observ
compound
test
show
signific
chang
k
presenc
trna
cellular
permeabl
toxic
assess
cell
toxic
first
examin
via
assay
triazolecontain
compound
significantli
less
toxic
previous
report
compound
figur
previou
data
shown
refer
compound
particular
essenti
nontox
highest
examin
concentr
although
previou
experi
produc
cluster
toxic
among
close
relat
analog
bind
fss
triazolecontain
compound
found
valu
previous
report
ref
b
valu
previous
report
ref
error
deriv
standard
deviat
mean
averag
individu
fit
spread
toxic
differ
compound
particularli
unexpect
compound
chemic
similar
compound
toxic
dose
td
compound
found
roughli
twice
toxic
td
flow
cytometri
reveal
permeabl
triazol
analog
larg
follow
methyl
pattern
tetranmethyl
compound
display
greatest
cell
permeabl
nonnmethyl
compound
least
support
inform
result
consist
trend
previous
observ
compound
unmethyl
olefin
tetramethyl
olefin
provid
figur
refer
evalu
compound
select
examin
effect
concentr
compound
cell
rnaseq
total
transcript
analyz
condit
set
significantli
alter
gene
rel
control
compound
two
concentr
compar
use
web
tool
interactivenn
one
sampl
behav
outlier
therefor
analysi
conduct
without
consid
sampl
disregard
outlier
sampl
reveal
transcript
statist
signific
chang
compoundtr
condit
figur
two
show
greater
chang
consid
biolog
signific
set
genbank
id
pseudogen
inclus
outlier
sampl
analysi
result
subset
transcript
call
differenti
express
therefor
although
priori
conclud
inclus
outlier
biolog
relev
exclus
produc
conserv
estim
compound
effect
cell
sampl
show
addit
transcript
signific
chang
includ
express
gene
earli
growth
respons
log
fold
chang
microtubul
associ
protein
light
chain
beta
log
fold
chang
phosphatidylinositol
type
beta
log
fold
chang
ubiquitin
specif
peptidas
log
fold
chang
test
concentr
lower
chang
metabol
indic
toxic
observ
vide
supra
compound
addit
chang
may
reflect
compounddepend
increas
cell
stress
examin
overal
howev
low
number
significantli
alter
transcript
particular
near
absenc
express
gene
alter
highlight
select
compound
despit
statu
leastselect
triazol
analog
studi
base
trna
competit
spr
next
examin
effect
triazolecontain
fss
rna
binder
pseudotyp
hiv
virion
product
infect
system
produc
cell
first
transfect
provir
hiv
plasmid
modifi
env
gene
delet
nef
gene
replac
green
fluoresc
protein
gfp
assist
virion
detect
quantit
cotransfect
vesicular
stomat
viru
type
g
vsvg
plasmid
provid
envelop
function
tran
enabl
product
singlecycl
infecti
virion
visual
gfp
product
fluoresc
microscopi
also
allow
qualit
assess
virion
product
produc
cell
virion
produc
incub
variou
concentr
compound
harvest
use
infect
tzmbl
report
cell
virion
quantiti
first
normal
via
elisa
assay
tzmbl
cell
express
luciferas
upon
infect
hiv
via
hiv
ltr
promot
provid
quantit
readout
infect
indinavir
fdaapprov
proteas
inhibitor
employ
posit
control
observ
compound
substanti
decreas
virion
product
concentr
depend
manner
evidenc
decreas
gfp
fluoresc
support
inform
virion
produc
less
infecti
infect
decreas
strongli
increas
concentr
compound
figur
new
compound
slightli
less
effect
previous
report
compound
offset
significantli
lower
toxic
western
blot
use
assess
effect
fssbind
compound
gaggagpol
ratio
use
antibodi
probe
new
compound
found
increas
amount
gagpol
rel
gag
strongest
effect
figur
also
examin
lysat
compoundtr
produc
cell
western
blot
signific
chang
gaggagpol
ratio
observ
rel
control
suggest
excess
gagpol
product
packag
virion
support
inform
confirm
activ
compound
replicationcompet
viru
examin
effect
compound
vari
concentr
compound
ad
condit
test
triplic
preliminari
experi
compound
onehalf
medium
harvest
day
postinfect
replac
equival
volum
medium
compound
medium
remov
examin
viral
particl
use
elisa
assay
procedur
repeat
day
postinfect
experi
reveal
doseand
timedepend
inhibit
hiv
iiib
three
compound
support
inform
low
compound
undetect
compound
level
viru
present
highest
dose
day
postinfect
subsequ
full
profil
obtain
compound
day
postinfect
figur
ic
valu
obtain
via
fourparamet
logist
fit
data
indic
similar
potenc
respect
somewhat
higher
potenc
compound
decreas
viru
due
inhibit
cell
growth
inde
cell
present
compoundtr
well
untreat
virusinfect
well
day
support
inform
measur
alamar
blue
assay
effect
strike
consist
compoundmedi
protect
virusinduc
apoptosi
effect
seen
antihiv
agent
compound
prove
toxic
hivinfect
cell
concentr
fsstarget
compound
inhibit
via
differ
mechan
exist
antivir
also
examin
abil
inhibit
multidrugresist
strain
viru
patientderiv
strain
resist
broad
rang
proteas
inhibitor
nucleosid
revers
transcriptas
inhibitor
nonnucleosid
revers
transcriptas
inhibitor
also
highli
cytopath
use
similar
protocol
employ
hiv
iiib
experi
detail
infect
human
cell
treat
dose
evalu
product
viru
elisa
cell
surviv
alamar
blue
day
postinfect
gratifi
observ
compound
inhibit
strain
provid
statist
signific
protect
cytopath
effect
figur
continu
need
develop
new
antihiv
therapi
particularli
explor
novel
therapeut
target
hiv
frameshift
recogn
time
attract
potenti
avenu
viral
inhibit
previous
lack
effect
strategi
sequenceselect
rna
recognit
made
address
target
challeng
past
work
demonstr
feasibl
degrad
infect
pseudotyp
hiv
via
fss
rnatarget
compound
demonstr
first
time
strategi
also
yield
compound
abl
strongli
inhibit
replic
laboratori
strain
hiv
human
cell
one
compound
inhibit
highli
cytopath
multidrugresist
strain
critic
step
valid
fss
rna
therapeut
target
also
import
note
frameshift
limit
wide
use
mani
pathogen
virus
exampl
sar
coronaviru
also
eukaryot
includ
human
recod
process
possibl
control
point
drive
therapeut
outcom
approach
appli
frameshift
extend
synthet
molecul
control
broad
rang
recod
event
broader
context
rna
recognit
work
also
demonstr
use
triazol
disulfid
bioisoster
effect
densiti
function
theori
dft
calcul
structur
depict
figur
minim
gamess
version
may
use
densiti
function
method
basi
set
van
der
waal
surfac
color
electrostat
potenti
visual
avogadro
synthesi
compound
compound
synthes
use
standard
solid
phase
peptid
protocol
wang
resin
mmolgram
alkyn
contain
monom
mmolgram
azid
contain
monom
activ
carbonyl
diimidazol
cdi
equiv
dimethylformamid
dmf
h
follow
treatment
equiv
dmf
h
amino
acid
coupl
use
equiv
aa
phe
pro
pra
aha
nmeph
equiv
hatu
equiv
dipea
dmf
h
deprotect
fmoc
accomplish
use
piperidin
dmf
h
nme
amino
acid
need
commerci
avail
fmoc
first
remov
use
standard
method
follow
treatment
resin
equiv
chlorid
nosylcl
equiv
collidin
dcm
h
activ
resin
treat
ml
tmsdiazomethan
ml
methanol
dcm
overnight
methyl
monitor
hplc
remov
nosyl
group
resin
treat
equiv
equiv
dbu
h
end
monom
cap
benzo
g
quinolin
form
substitut
triazol
ring
azidecontain
peptid
cleav
trifuoroacet
acid
tfa
triethyl
silan
te
water
ether
precipit
yield
crude
yellow
solid
use
without
purif
next
resinbound
alkyn
dri
vacuum
wash
three
time
dri
thf
cui
equiv
dipea
equiv
ad
vessel
anhydr
thf
mix
min
azid
equiv
base
resin
load
ad
result
greenbrown
solut
mix
overnight
resin
wash
three
time
thf
three
time
dcm
three
time
dmf
three
time
dcm
cleav
tfa
te
water
h
follow
rotari
evapor
ether
precipit
surfac
plasmon
reson
spr
conduct
use
biacor
x
biacor
inc
instrument
streptavidin
immobil
ru
flow
cell
use
edcnh
coupl
chip
ge
surfac
block
ethanolamin
next
fss
obtain
hplcpurifi
sampl
integr
dna
technolog
inc
refold
mm
hepe
mm
nacl
ph
heat
heater
block
min
cool
rt
immobil
one
flow
cell
spr
chip
densiti
ru
control
flow
cell
block
inject
biotin
mm
hepe
mm
nacl
ph
compound
inject
flow
rate
mm
hepe
mm
nacl
tween
ph
min
inject
repeat
twice
consist
trace
fit
individu
langmuir
model
cytotox
assay
cell
plate
cellswel
plate
dmem
fetal
bovin
serum
penicillinstreptomycin
cell
allow
adher
h
incub
compound
h
triplic
total
premix
clontech
ad
incub
h
follow
measur
use
perkinelm
enspir
plate
reader
line
provid
logist
fit
data
flow
cytometri
cell
grown
dmem
fetal
bovin
serum
confluenc
plate
treat
compound
h
cell
trypsin
pellet
wash
twice
dpb
gibco
cell
resuspend
ice
cold
dpb
incub
propidium
iodid
stain
dead
cell
total
event
collect
use
bd
lsrii
flow
cytomet
rnaseq
cell
plate
sixwel
plate
allow
grow
confluencey
million
cell
treat
h
triplic
cell
process
accord
valid
protocol
develop
univers
rochest
genom
research
center
analyz
rnaseq
illumina
sequenc
read
clean
accord
rigor
preprocess
workflow
map
human
refer
genom
gencod
version
human
gene
annot
use
perform
differenti
express
analysi
fals
discoveri
rate
fdr
cutoff
confid
interv
pseudotyp
infect
antivir
activ
rnatarget
compound
measur
singleround
infect
assay
pseudotyp
use
produc
cell
provir
vector
includ
gene
except
nef
replac
gfp
env
thu
preserv
gag
pol
frameshift
requir
product
gagpol
polyprotein
singleround
infect
assay
conduct
transient
transfect
viral
vector
vsvg
coat
protein
vector
ratio
use
fugen
hd
promega
viru
produc
cell
dose
compound
h
transfect
viral
particl
harvest
media
h
transfect
filter
syring
filter
viral
load
normal
elisa
perkinelm
infect
perform
use
tzmbl
report
cell
contain
stabli
integr
firefli
luciferas
express
driven
hivltr
promot
therefor
luciferas
express
upon
success
hiv
infect
triplic
infect
plate
cellswel
pg
proceed
h
addit
steadyglo
reagent
promega
well
min
luminesc
measur
quantit
metric
chang
viral
infect
presenc
compound
cell
obtain
nih
aid
reagent
program
grown
rpmi
media
supplement
fetal
bovin
serum
cell
seed
cell
cultur
flask
ml
infect
hiv
iiib
concentr
ng
infect
allow
proceed
h
humidifi
incub
cell
collect
centrifug
min
excess
viru
remov
cell
wash
dpb
cell
resuspend
fresh
growth
media
plate
cultur
dish
cellswel
compound
ad
cell
triplic
final
concentr
total
volum
brought
mlwell
day
postinfect
ml
supernat
collect
well
replac
ml
fresh
media
compound
correspond
concentr
given
day
postinfect
ml
supernat
collect
alamar
blue
cell
viabil
reagent
thermofish
ad
well
alamar
blue
fluoresc
measur
exem
nm
bandwidth
supernat
frozen
subsequ
analysi
viral
load
via
elisa
accord
manufactur
instruct
advanc
bioscienc
laboratori
alamar
blue
elisa
plate
read
mulitmod
detector
beckman
coulter
support
inform
avail
free
charg
ac
public
websit
doi
